-
2021 NCCN and CSCO Breast Cancer Guidelines Update
Time of Update: 2022-01-09
Advanced rescue treatment points 8 Advanced triple-negative breast cancer first-line first-line first-line option is newly added "Pembrolizumab + chemotherapy (albumin combined with paclitaxel, paclitaxel, gemcitabine and carboplatin)", the patient is PD-L1 positive (CPS score> 10 points ) .
-
IMmotion151 research final OS results released
Time of Update: 2022-01-09
The interim analysis of the IMmotion151 study showed that atilizumab + bevacizumab compared with sunitinib can significantly improve the progression-free survival (PFS) of patients, reaching the primary study endpoint .
-
Real-world study results of Venecla in the treatment of patients with relapsed and refractory multiple myeloma
Time of Update: 2022-01-09
In t(11;14) patients, the median OS of patients with and without high-risk cytogenetic abnormalities was 13 months and not reached (P<0.
Among patients without t(11;14), the median OS of patients with and without high-risk cytogenetics was 10 months and not reached (P=0.
-
BMJ: Pathological complete remission should not be used as the primary endpoint of breast cancer neoadjuvant treatment studies
Time of Update: 2022-01-09
*Only for medical professionals to read for reference, 1 minute a day, to give you professional "talking information" in the tumor circle! (If you need the original text of the literature, you can ad
-
Progress in Macrophage Tumor Immunotherapy
Time of Update: 2022-01-09
Through innate immune cell therapy, the development of effective phagocyte targets and the search for new innate immune checkpoints are important strategies to improve the response rate of tumor immunotherapy .
-
Chinese study: PI3K/AKT pathway activation is a potential mechanism of small cell lung cancer treatment resistance
Time of Update: 2022-01-09
Enrichment of genome changes after radiotherapy and chemotherapy In the PI3K/AKT pathway, the genome profiles of newly treated and recurring SCLC tumors are first compared to determine the genomes related to recurrence after CCRT .
-
Late mortality and life expectancy of Allo-HSCT recipients in the past 40 years
Time of Update: 2022-01-09
Based on this, some researchers have carried out a blood or bone marrow transplant survivor study (BMTSS) to analyze the cumulative impact of long-term complications and early mortality of Allo-HSCT recipients on life expectancy .
-
A new end point for MM treatment?
Time of Update: 2022-01-09
The results of the study showed that compared with placebo, ixazomib can significantly improve the PFS of MRD+ patients at the time of enrollment (median PFS 18.
-
7 tables to master the NCCN guidelines for 2022 v1 NSCLC treatment options
Time of Update: 2022-01-09
*It is only for medical professionals to read the reference.
Recently, the National Cancer Network (NCCN) updated the 2022 v1 non-small cell lung cancer (NSCLS) diagnosis and treatment guidelines .
The guide is updated, one step ahead!
-
Professor Jiang Zefei: Looking back and looking forward to comprehensively promoting a new model of breast cancer diagnosis and treatment in multiple fields and new situations
Time of Update: 2022-01-09
Gallen Breast Cancer Conference, the international expert group online meeting as scheduled, to promote the overall development of the breast cancer field Professor Jiang Zefei once a year The annual review meeting of breast cancer treatment progress is coming as scheduled.
-
Sub-Journal of "Cell": This bacteria can really fight cancer!
Time of Update: 2022-01-09
Recently, an article published on Cancer Cell proposed , A kind of probiotics and their metabolites that naturally exist in our intestines-Lactobacillus reuteri and Reuterin, can also effectively inhibit the development of colorectal cancer (CRC) [1 ] .
-
Colorectal cancer (CRC) monoclonal antibody, double antibody and CAR-T therapy
Time of Update: 2022-01-09
A phase II trial study showed that cetuximab has moderate anti-tumor activity once a week intravenously, and it is well tolerated in patients with CRC who are refractory to chemotherapy .
-
The whole course of neoadjuvant treatment for rectal cancer: the order of chemotherapy and radiochemotherapy
Time of Update: 2022-01-09
A previous multicenter, randomized phase 2 trial in Germany enrolled 306 patients with stage II or III rectal cancer who received a full course of neoadjuvant therapy (CAO/ARO/AIO-12; J Clin Oncol 2019; 37:3212).
-
Targeting CD79b!
Time of Update: 2022-01-09
On December 21, 2021, CDE included Vibotuzumab in the proposed priority review for the treatment of adult patients with relapsed or refractory diffuse large B lymphoma (DLBCL) .
-
[Research] The mechanism that destroys the proliferation of cancer cells and induces their death—bringing new cancer treatment strategies
Time of Update: 2022-01-09
Studies have found that autophagy regulation is a new treatment strategy for cancer: drugs that induce high levels of autophagy can cause the collapse of tumor cells and the activation of apoptotic cell death programs .
-
Reduce CD3 affinity-the application of CD3 double antibodies in the treatment of solid tumors
Time of Update: 2022-01-09
The in vivo efficacy and cytokine release of MUC16-CD3 double antibodies with different affinities in a mouse tumor model The tissue distribution of Amgen’s AMG757 CD3 double antibody for solid tumor treatment is mainly based on the HLE BiTE platform.
-
The 2021 version of the guidelines for the clinical application of new anti-tumor drugs is released!
Time of Update: 2022-01-09
The "Guiding Principles" emphasize that the clinical application of anti-tumor drugs must follow the drug instructions and cannot be used beyond the indications at will .
-
Focusing on the progress of diagnosis and treatment of neuroblastoma, focusing on the landing of targeted immunotherapy-"Neuroblastoma Targeted Immunity Frontier Forum" conference report
Time of Update: 2022-01-09
Professor Xiaowen Zhai of the Children's Hospital of Fudan University stated in his opening speech that 2021 will be a special year for domestic high-risk patients with goddesses, because two GD2 targeted immunotherapy drugs have been introduced into China .
-
"Blood test for cancer" female version of Jobs convicted, is liquid biopsy reliable? NEJM review
Time of Update: 2022-01-09
In addition, compared with needle aspiration biopsy of a single tumor lesion, cfDNA analysis can better detect the molecular heterogeneity of multiple different clonal populations in a patient's tumor .
-
"Logic gate" AAV gene therapy, let cancer cells "nowhere to escape" Medical Maihei Technology
Time of Update: 2022-01-09
Recently, a team of scientists from the Swiss Federal Institute of Technology Zurich has developed a logic-gated AAV gene therapy, which is used in combination with Roche's antiviral drug Cytovene (ganciclovir) in a mouse model of hepatocellular carcinoma It shows the potential of precisely targeting cancer cells, and can kill cancer cells more effectively while preserving healthy tissues, significantly reducing the tumor burden of hepatocellular carcinoma mice .
